TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19386947
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) alone
Study: 23067366
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/day for 12 months
Study: 16608035
Drug: Intraoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative adjuvant therapy (hepatectomy plus microwave coagulonecrotic therapy or radiofrequency ablation)
Study: 16608035
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant therapy (transcatheter arterial embolization)
Study: 9375593
Drug: Pimozide treatment
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide treatment for 6 weeks
Study: 3890521
Drug: Oral glucose-electrolyte
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose-electrolyte solution with 60 mEq/L sodium and 2% glucose
Study: 3890521
Drug: Oral glucose-electrolyte
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose-electrolyte solution with 30 mEq/L sodium and 5% glucose
Study: 27121539
Drug: Daily buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine-naloxone (BP-NLX)
Study: 23734933
Drug: Telaprevir-based triple
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir-based triple therapy (T12/PR24 group)
Study: 20484150
Drug: Hydrocortisone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (0.6 mg/kg i.v. bolus)
Study: 3516407
Drug: Glycinated aspirin
Normalized name: aspirin / glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycinated aspirin swallowed without water (600 mg)
Study: 3516407
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin swallowed with water (600 mg)
Study: 3516407
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Glycinated aspirin and Soluble aspirin)
Study: 26613823
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg ethinyl estradiol (EE) with 3mg drospirenone
Study: 26613823
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ethinyl estradiol (EE) with 3mg drospirenone
Study: 26573461
Drug: Cost-per-vaccinated child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-per-vaccinated child excluding vaccine purchase
Study: 15985589
Drug: Early withdrawal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early withdrawal of antiepileptic drugs
Study: 10543667
Drug: Nitrendipine 5
Normalized name: nitrendipine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 5 mg twice daily
Study: 10543667
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg twice daily
Study: 8677941
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (natural alpha-interferon, 6 MU daily for 2 weeks, then 3 times a week for 22 weeks)
Study: 8677941
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (natural alpha-interferon, 6 MU daily for 8 weeks, then 2 times a week for 12 weeks)
Study: 29993146
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/d plus adapalene gel 0.1%
Study: 21561497
Drug: Stepped smoking
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped smoking cessation intervention based on the transtheoretical model of change, involving 6-month implementation of recommendations from a Clinical Practice Guideline including brief motivational interviews, brief intervention, intensive intervention with pharmacotherapy, and reinforcing intervention.
Study: 16686908
Drug: Prophylaxis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis treatment for migraine
Study: 2125252
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy alone
Study: 8989010
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of hetastarch solution
Study: 8989010
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL of lactated Ringer's solution
Study: 7655330
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day ground flaxseed
Study: 2106401
Drug: Procainamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (750 mg)
Study: 2106401
Drug: Tocainide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (600 mg)
Study: 2106401
Drug: Encainide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide (50 mg)
Study: 346257
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg per day) for 7 days
Study: 21969227
Drug: Vorapaxar 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 40 mg single dose
Study: 21969227
Drug: Vorapaxar 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 2.5 mg daily maintenance dose
Study: 21969227
Drug: Vorapaxar (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (various doses: 5, 10, 20, or 40 mg single doses; 0.5, 1, or 2.5 mg once daily)
Study: 21969227
Drug: Vorapaxar (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (various doses)
Study: 19852833
Drug: Erythropoietin dose
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin dose
Study: 17443852
Drug: Synbiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics + neomycin + mechanical bowel preparation (MBP)
Study: 17443852
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation only
Study: 17443852
Drug: Neomycin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin + mechanical bowel preparation (MBP)
Study: 17443852
Drug: Synbiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics + neomycin without mechanical bowel preparation (MBP)
Study: 14995924
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg daily for 10 days
Study: 14995924
Drug: Promethazine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 75 mg daily for 10 days
Study: 8373713
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg
Study: 28413900
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + medication
Study: 30110009
Drug: Aroma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aroma therapy
Study: 30110009
Drug: Joint-therapy (aroma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint-therapy (aroma therapy + music intervention)
Study: 26036329
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine
Study: 25322165
Drug: Long-pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed Nd:YAG laser treatment
Study: 25322165
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Oral terbinafine + Long-pulsed Nd:YAG laser)
Study: 17624052
Drug: Heparin-coated catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated catheter with 50 mL/d of normal saline solution as a continuous infusion
Study: 16291713
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of prochlorperazine
Study: 16291713
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of prochlorperazine, twice daily
Study: 16291713
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet of prochlorperazine
Study: 7769597
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 1.0 mg (n = 30)
Study: 7769597
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.75 mg (n = 30)
Study: 17667723
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) 3 x 10 colony-forming units, twice daily for 4 weeks
Study: 15363567
Drug: Transurethral ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transurethral ethanol ablation of the prostate (TEAP) using ProstaJect device, average ethanol injected 14 ml.
Study: 7979340
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of sucrose
Study: 7979340
Drug: 4.34 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.34 g of saccharin
Study: 2806714
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of atenolol (100 mg)
Study: 2806714
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of atenolol (100 mg)
Study: 27346074
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg orally) on the day before, the day, and the day after TUR-BT
Study: 27346074
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg orally)
Study: 26327130
Drug: AJM300 (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 (960 mg)
Study: 20947097
Drug: Lung lavage
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung lavage with dilute bovine surfactant (two 15‐mL/kg aliquots)
Study: 10971827
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy for 16 or 32 weeks
Study: 10971827
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after 16 weeks
Study: 10971827
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment for another 16 weeks
Study: 8627059
Drug: High-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose didanosine (ddI) 375 mg twice daily
Study: 8627059
Drug: Low-dose didanosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose didanosine (ddI) 100 mg twice daily
Study: 9870319
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) monotherapy
Study: 29420536
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate hydration (250 ml 1.4%)
Study: 29420536
Drug: Saline hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline hydration (1000 ml 0.9%)
Study: 20722643
Drug: Double-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose misoprostol 25 microg
Study: 20722643
Drug: Dinoprostone 3
Normalized name: dinoprostone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone 3 mg
Study: 28402415
Drug: Single-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose misoprostol
Study: 11912072
Drug: MMT (Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMT (Methadone Maintenance Treatment)
Study: 11912072
Drug: N-MMT (Non-Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-MMT (Non-Methadone Maintenance Treatment)
Study: 10522982
Drug: Androderm testosterone
Normalized name: testosterone Transdermal System [Androderm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androderm testosterone transdermal system (TTD) - two 2.5-mg systems applied nightly
Study: 10522982
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone enanthate (i.m.) - 200 mg injected every 2 weeks
Study: 8706192
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg (n = 25)
Study: 8706192
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg (n = 25)
Study: 7261688
Drug: Talampicillin (TMP)
Normalized name: talampicillin
DrugBank: Talampicillin (DB13814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talampicillin (TMP) 325 mg (equivalent to 200 mg ampicillin)
Study: 7261688
Drug: Ampicillin (AMP)
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin (AMP) 500 mg
Study: 19890693
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine injections during ESDs (mean dose 236 mg, mean volume 55.4 ml)
Study: 19890693
Drug: Conventional normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional normal saline solution injections during ESDs (control group)
Study: 19890693
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine injections during ESDs (LG)
Study: 9305556
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 g in 500 ml NSaline)
Study: 8285082
Drug: Antacid containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid containing aluminum hydroxide
Study: 3543246
Drug: 5-FU (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (1,000 mg/m2 days 1 through 4) with bolus FA (200 mg/m2 days 1 through 4) - infusion arm
Study: 3543246
Drug: 5-FU (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (325 mg/m2 days 1 through 5) with bolus FA (200 mg/m2 days 1 through 5) - bolus arm
Study: 26825109
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intervention beyond regular osteoporosis treatment)
Study: 31950924
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mirabegron
Study: 23079373
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mirabegron
Study: 17136293
Drug: Second-generation antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antihistamines
Study: 17136293
Drug: Third-generation antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation antihistamines
Study: 15078430
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg single dose vaginal tablet (VT)
Study: 15078430
Drug: Clotrimazole 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 10% single dose vaginal cream (VC)
Study: 15078430
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg single dose oral capsule (Diflucan)
Study: 15078430
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg VT and Clotrimazole 10% VC
Study: 15078430
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Clotrimazole and Fluconazole)
Study: 8001522
Drug: Riboflavin intake
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin intake (average daily intake above 0.5 mg/1000 kcal)
Study: 9084065
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral adinazolam mesylate SR tablets
Study: 9084065
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg parenteral (i.v.) adinazolam mesylate
Study: 9084065
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg i.v. NDMAD
Study: 8441129
Drug: Cream based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream based preparation
Study: 3538742
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin infusion (1 1/2 to 2 1/4 min pulses followed by 10 1/2 to 9 3/4 min intervals)
Study: 3538742
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (0.45 mU/kg X min)
Study: 27171969
Drug: Topical Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Furosemide
Study: 24719126
Drug: Intracoronary abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary abciximab (0.25 mg/kg)
Study: 21098442
Drug: Intravenous abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous abciximab (0.25 mg/kg)
Study: 18950458
Drug: DaunoXome (DNX)
Normalized name: daunorubicin liposomal Injection [DaunoXome]
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DaunoXome (DNX) 80 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Study: 18950458
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 45 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Study: 15899106
Drug: Ezetimibe 10mg
Normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10mg co-administered with simvastatin 10mg or 20mg
Study: 15899106
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with simvastatin 10mg or 20mg
Study: 11780237
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing combined with local application of 2% minocycline hydrochloride ointment (Periocline)
Study: 8829939
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg intramuscularly (i.m.)
Study: 8829939
Drug: ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg intramuscularly (i.m.)
Study: 8829939
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg orally
Study: 8829939
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL NaCl i.m.
Study: 31995688
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days)
Study: 31995688
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in treatment group
Study: 30243993
Drug: Elevated Syndecan-1
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated Syndecan-1 levels (≥ 40 ng/mL)
Study: 22414352
Drug: Transpapillary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transpapillary injection
Study: 22414352
Drug: Conventional palatal
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional palatal injection
Study: 20814766
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (ALA) intake (1.2-3.6 g/d)
Study: 17692522
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (5000lx, 100 cm distance)
Study: 15866495
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg AJA
Study: 1828420
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg
Study: 1693732
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg
Study: 1414299
Drug: Indomethacin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 1% ophthalmic solution
Study: 2865930
Drug: PMP +
Normalized name: C(PMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMP + D-penicillamine (DPA) - 500 mg/day
Study: 2865930
Drug: PMP +
Normalized name: C(PMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMP + sulphasalazine (SAS) - 2.0 g/day
Study: 28631896
Drug: 0.75% Boric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% Boric acid gel
Study: 24801644
Drug: Infusion set
Normalized name: INFUSION SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion set placed on the buttock
Study: 24801644
Drug: Infusion set
Normalized name: INFUSION SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion set placed on the abdomen
Study: 20237221
Drug: Various proposed
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various proposed solutions to improve value in cancer care; specific interventions not detailed.
Study: 16162440
Drug: Ciprofibrate treatment
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate treatment
Study: 12941195
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy using goserelin (LHRH agonist)
Study: 12941195
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy using bilateral orchiectomy
Study: 12941195
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy using bicalutamide 150 mg